Home » Newsletters » BioWorld Science

BioWorld Science

June 30, 2011

View Archived Issues

Encouraging phase I data presented on GDC-0068 and GDC-0941 in cancer

Cixutumumab monotherapy is not beneficial in phase II hepatocellular carcinoma trial

Preliminary first-in-human results indicate ATU-027 RNAi therapy is well tolerated

New modulators of lysophospholipid S1P1 receptor presented

Phase III trial evaluates linagliptin/metformin combination in type 2 diabetes

Boehringer Ingelheim discloses new ribosomal protein S6 kinase alpha-3 inhibitors

Galderma presents novel peroxide derivatives for acne

CNX-011-67 improves responsiveness to glucose in models of diabetes

BioAlliance Pharma submits application to French Drug Agency for phase III Livatag trial

Phase I trial assesses TPI-287 with and without temozolomide in neuroblastoma/medulloblastoma

EpiCept receives initial responses from FDA regarding SPA application for Ceplene in AML

Living Cell Technologies begins enrollment in phase II Diabecell trial

Scientists at Sanofi design new pim kinase inhibitors for cancer

Dosing begins in phase I trial of antisense therapy ATL-1103

Japanese MAA submitted for Eylea for wet AMD

Medivir patents new cathepsin S inhibitors

Cardium Therapeutics to acquire Transdel Pharmaceuticals

FDA grants orphan drug status to anticancer product MDX-1097

Cynapsus provides update on oral apomorphine for Parkinson's disease

CHMP recommends approval of Eurartesim for malaria

Enrollment complete in phase III MOTION trial of safinamide in early Parkinson's disease

Health Canada approves Tasigna for newly diagnosed Ph+ CML

FDA accepts for review Pfizer's application for axitinib in advanced renal cell carcinoma

Progenics submits sNDA for Relistor for OIC in patients with chronic noncancer pain

Phase I/II trial of 2B3-101 to begin in patients with brain metastases

Torrent Pharmaceuticals' new HSP70 inducer TRC-051384 reduces symptoms of stroke in vivo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Anticancer drug exerts potent HIV antiviral effects
BioWorld Science
A new isoform of proliferating cell nuclear antigen (PCNA) – cancer-associated PCNA (caPCNA) – that is specifically expressed in cancer tissues has been reported....